aldesleukin + cyclophosphamide

Aldesleukin is a recombinant interleukin-2 (IL-2) cytokine that stimulates the proliferation and activation of immune cells, particularly T lymphocytes and natural killer cells, enhancing antitumor immune responses. Cyclophosphamide is an alkylating nitrogen mustard chemotherapeutic agent that requires hepatic activation to form active metabolites which crosslink DNA, leading to cytotoxicity in rapidly dividing cells including cancer cells. The combination of aldesleukin with cyclophosphamide is used as an immunochemotherapy regimen aiming to both directly kill tumor cells via chemotherapy and stimulate the immune system to attack tumors. Aldesleukin has been used primarily for metastatic melanoma and renal cell carcinoma treatment; cyclophosphamide treats various malignancies including lymphomas, leukemias, ovarian adenocarcinoma, breast carcinoma among others. The combination has been explored in clinical trials for metastatic melanoma and other cancers with the goal of improving response rates by combining immunostimulation with cytotoxic chemotherapy[1][2][3].

Brand names

ProleukinCytoxan

Other names

aldesleukin-Western Regional Medical Center-melanoma (metastatic)IL-2IL2IL 2Interleukin-2Interleukin2Interleukin 2cyclophosphamidelow-dose cyclophosphamide and outpatient interleukin-2